Key result
Beta-blockers and angiotensin II-receptor blockers attenuate the clinical manifestations of Marfan syndrome, an autosomal dominant condition with an incidence of 1 in 3000 to 5000 individuals.
Answers are grounded in this paper and cite their sources.
Beta-blockers and angiotensin II-receptor blockers are noted to improve aortic properties and attenuate clinical manifestations of Marfan syndrome.
Marfan syndrome (MFS) is an autosomal dominant condition with a reported incidence rate of 1 in 3000 to 5000 individuals. The majority of cases of MFS are caused by a mutation in the fibrillin-1 gene (FBN1). Transforming growth factor (TGF-) plays an important role in Marfan syndrome. The identification of the FBN-1 mutation will help identify potentially affected family members and promote prenatal diagnostic testing. blockers decrease myocardial contractility and pulse pressure and may also improve the elastic properties of the aorta. Angiotensin II-receptor blockers attenuate the clinical manifestations of MFS.
No takes yet. Share an insight, caveat, or question.
Zacharias et al. (2017) conducted a review in Marfan syndrome. Beta-blockers and angiotensin II-receptor blockers attenuate the clinical manifestations of Marfan syndrome, an autosomal dominant condition with an incidence of 1 in 3000 to 5000 individuals.
Synapse has enriched 10 related papers. Consider them for comparative context: